403 related articles for article (PubMed ID: 34686340)
1. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
[TBL] [Abstract][Full Text] [Related]
2. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
3. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
4. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
5. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Molgora M; Esaulova E; Vermi W; Hou J; Chen Y; Luo J; Brioschi S; Bugatti M; Omodei AS; Ricci B; Fronick C; Panda SK; Takeuchi Y; Gubin MM; Faccio R; Cella M; Gilfillan S; Unanue ER; Artyomov MN; Schreiber RD; Colonna M
Cell; 2020 Aug; 182(4):886-900.e17. PubMed ID: 32783918
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
7. CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer.
Marcovecchio PM; Thomas G; Salek-Ardakani S
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637602
[TBL] [Abstract][Full Text] [Related]
8. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Beyranvand Nejad E; Labrie C; van Elsas MJ; Kleinovink JW; Mittrücker HW; Franken KLMC; Heink S; Korn T; Arens R; van Hall T; van der Burg SH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879600
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
10. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
11. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
Carosella ED; Gregori S; Tronik-Le Roux D
Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
14. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
17. Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
Ardighieri L; Missale F; Bugatti M; Gatta LB; Pezzali I; Monti M; Gottardi S; Zanotti L; Bignotti E; Ravaggi A; Tognon G; Odicino F; Calza S; Missolo-Koussou Y; Ries CH; Helft J; Vermi W
Front Immunol; 2021; 12():690201. PubMed ID: 34220848
[TBL] [Abstract][Full Text] [Related]
18. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjärvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikström SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32005-32016. PubMed ID: 33229588
[TBL] [Abstract][Full Text] [Related]
19. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
[TBL] [Abstract][Full Text] [Related]
20. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]